Overall survival (OS) in patients (pts) with advanced breast cancer (ABC) with visceral metastases (mets), including those with liver mets, treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials.
暂无分享,去创建一个
P. Neven | D. Slamon | S. Chia | Y. Yap | D. Yardley | T. Bachelot | G. Sonke | P. Wheatley‐Price | A. Chan | A. Nusch | A. Lteif | M. Sondhi | K. Rodriguez-Lorenc | A. Gaur | Manu Sondhi | Karen Rodriguez-Lorenc | P. Wheatley-Price